Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: Effects of varying the relative orientation of the berberine and INF55 components

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3219-3224

  Tomkiewicz, Danuta ^b   Casadei, Gabriele ^b   Larkins Ford, Jonah ^c,d   Moy, Terence I ^c,d,e   Garner, James ^a,f   Bremner, John B ^a   Ausubel, Frederick M ^c,d   Lewis, Kim ^b   Kelso, Michael J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b NORTHEASTERN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CUBIST PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 NITRO 2 PHENYLINDOLE; ANTIINFECTIVE AGENT; BERBERINE; BERBERINE 5 NITRO 2 PHENYLINDOLE HYBRID AGENT; ETHIDIUM BROMIDE; INF 55; MULTIDRUG RESISTANCE PROTEIN; PROTEIN NORA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CAENORHABDITIS ELEGANS; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; GENE OVEREXPRESSION; HYBRID; INHIBITION KINETICS; ISOMER; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BERBERINE; CAENORHABDITIS ELEGANS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ETHIDIUM; INDOLES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955379580     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01715-09     Document Type: Article

References (37)

1. Amin, A. H., T. V. Subbaiah, and K. M. Abbasi. 1969. Berberine sulfate: antimicrobial activity, bioassay and mode of action. Can. J. Microbiol. 15:1067-1076.
2. Ball, A. R., G. Casadei, S. Samosorn, J. B. Bremner, F. M. Ausubel, T. I. Moy, and K. Lewis. 2006. Conjugating berberine to a multidrug resistance pump inhibitor creates an effective antimicrobial. ACS Chem. Biol. 1:594-600.
3. Barbachyn, M. R. 2008. Recent advances in the discovery of hybrid antibacterial agents. Annu. Rep. Med. Chem. 43:281-290.
4. Beanan, M. J., and S. Strome. 1992. Characterization of a germ-line proliferation mutation in C. elegans. Development 116:755-766.
5. Bremner, J. B. 2007. Some approaches to new antibacterial agents. Pure Appl. Chem. 79:2143-2153.
6. Bremner, J. B., J. I. Ambrus, and S. Samosorn. 2007. Dual action-based approaches to antibacterial agents. Curr. Med. Chem. 14:1459-1477.
7. Bremner, J. B., and M. J. Kelso. Synthesis of berberine-efflux pump inhibitor hybrid antibacterials. Synth. Commun., in press.
8. Brooks, B. R., R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus. 1983. CHARMM: a program for macromolecular energy minimization and dynamics calculations. J. Comput. Chem. 4:187-217.
9. Charifson, P. S., A.-L. Grillot, T. H. Grossman, J. D. Parsons, M. Badia, S. Bellon, D. D. Deininger, J. E. Drumm, C. H. Gross, A. LeTiran, Y. Liao, N. Mani, D. P. Nicolau, E. Perola, S. Ronkin, D. Shannon, L. L. Swenson, Q. Tang, P. R. Tessier, S.-K. Tian, M. Trudeau, T. Wang, Y. Wei, H. Zhang, and D. Stamos. 2008. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure guided design and structure-activity relationships. J. Med. Chem. 51:5243-5263.
10. Davies, J. 2007. Microbes have the last word. EMBO Rep. 8:616-621.
11. German, N., P. Wei, G. W. Kaatz, and R. J. Kerns. 2008. Synthesis and evaluation of fluoroquinolone derivatives as substrate based inhibitors of bacterial efflux pumps. Eur. J. Med. Chem. 43:2453-2463.
12. Hseih, P. C., S. A. Siegel, B. Rogers, S. Davis, and K. Lewis. 1998. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc. Natl. Acad. Sci. U. S. A. 95:6602-6606.
13. Huang, J. Z., P. W. O'Toole, W. Shen, H. Amrine-Madsen, X. H. Jiang, N. Lobo, L. A. Palmer, L. Voelker, F. Fan, M. N. Gwynn, and D. McDevitt. 2004. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob. Agents Chemother. 48:909-917.
14. Huycke, M. M., C. A. Spiegel, and M. S. Gilmore. 1991. Bacteremia caused by hemolytic high-level gentamycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 35:1626-1634.
15. Iwasa, K., M. Kamigauchi, M. Ueki, and M. Taniguchi. 1996. Antibacterial activity and structure-activity relationships of berberine analogs. Eur. J. Med. Chem. 31:469-478.
16. Kaatz, G. W. 2006. Bacterial efflux pump inhibition. Curr. Opin. Invest. Drugs 6:191-198.
17. Kaatz, G. W., and S. M. Seo. 1997. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2733-2737.
18. Kaatz, G. W., F. McAleese, and S. M. Seo. 2005. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob. Agents Chemother. 49:1857-1864.
19. Li, X.-Z., and H. Nikaido. 2004. Efflux-mediated drug resistance. Drugs 64:159-204.
20. Lomovskaya, O., and K. A. Bostian. 2006. Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem. Pharmacol. 71:910-918.
21. Lomovskaya, O., H. I. Zgurskaya, K. A. Bostian, and K. Lewis. 2008 Multidrug efflux pumps: structure, mechanism, and inhibition, p. 45-69. In R. G. Wax, K. Lewis, A. A. Salyers and H. Taber (ed.), Bacterial resistance to antimicrobials, 2nd ed. CRC Press-Taylor and Francis Group, Boca Raton, FL.
22. Markham, P. N., E. Westhaus, K. Klyachko, M. E. Johnson, and A. A. Neyfakh. 1999. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2404-2408.
23. Momany, F. A., and R. Rone. 1992. Validation of the general purpose QUANTA 3.2/CHARMm forcefield. J. Comput. Chem. 13:888-900.
24. Moy, T. I., A. R. Ball, Z. Anklesaria, G. Casadei, K. Lewis, and F. M. Ausubel. 2006. Identification of novel antimicrobials using a live animal infection model. Proc. Natl. Acad. Sci. U. S. A. 103:10414-10419.
25. Narui, K., N. Noguchi, K. Wakasugi, and M. Sasatsu. 2002. Cloning and characterization of a novel chromosomal drug efflux gene in Staphylococcus aureus. Biol. Pharm. Bull. 25:1533-1536.
26. Neyfakh, A. A., C. M. Borsch, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.
27. Nordmann, P., T. Naas, N. Fortineau, and L. Poirel. 2007. Superbugs in the coming decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa I 2010. Curr. Opin. Microbiol. 10:436-440.
28. Poole, K. 2007. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 39:162-176.
29. Price, C. T. D., G. W. Kaatz, and J. E. Gustafson. 2002. The multidrug efflux pump NorA is not required for salicylate-induced reduction in drug accumulation by Staphylococcus aureus. Int. J. Antimicrob. Agents 20:206-213.
30. Rice, L. B. 2006. Unmet medical needs in antibacterial therapy. Biochem. Pharmacol. 71:991-995.
31. Samosorn, S., B. Tanwirat, N. Muhamad, G. Casadei, D. Tomkiewicz, K. Lewis, A. Suksamrarn, T. Prammananan, K. C. Gornall, J. L. Beck, and J. B. Bremner. 2009. Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group. Bioorg. Med. Chem. 17:3866-3872.
32. Samosorn, S., J. B. Bremner, A. Ball, and K. Lewis. 2006. Synthesis of functionalized 2-aryl 5-nitro-1H-indoles and their activity as bacterial NorA effux pump inhibitors. Bioorg. Med. Chem. 14:857-865.
33. Severina, I. I., M. S. Muntyan, K. Lewis, and V. P. Skulachev. 2001. Transfer of cationic antibacterial agents berberine, palmatine and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane. IUBMB Life 52:321-324.
34. Stermitz, F. R., P. Lorenz, J. N. Tawara, L. Zenewicz, and K. Lewis. 2000. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl. Acad. Sci. U. S. A. 97:1433-1437.
35. 2+ signaling to determine neuronal asymmetric development in Caenorhabditis elegans. EMBO Rep. 3:56-62.
36. Truong-Bolduc, Q. C., J. Strahilevitz, and D. C. Hooper. 2006. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1104-1107.
37. Yamada, Y., K. Hideka, S. Shiota, T. Kuroda, and T. Tsuchya. 2006. Gene cloning and characterization of SdrM, a chromosomally-encoded multidrug efflux pump from Staphylococcus aureus. Biol. Pharm. Bull. 29:554-556.